STE vs SYRE
Steris vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
VS
SYRE
Spyre Therapeutics, Inc.
67
Buy
| Metric | STE | SYRE |
|---|
| AI Score |
54
|
67
|
| Price |
$237.96
|
$106.50
|
| P/E Ratio |
29.02×
|
-54.61×
|
| ROE |
10.9%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
44.4%
|
0.0%
|
| Debt / Equity |
0.28×
|
0.00×
|
| Dividend Yield |
1.1%
|
0.0%
|
| RSI (14) |
62.9
|
57.1
|
| Beta |
0.914
|
3.026
|
| Expected Upside |
+6.2%
|
—
|
AI Committee View
Current Innellis committee reasoning for STE versus SYRE.
SYRE leads by 13 points.
SYRE scores 67/100 (Buy) versus STE at 54/100 (Watch).
STE Committee View
50% agreement
4 analysts
The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+0.33 across 9 articles, 14d). Growth Analyst remains cautious — growth rate is decelerating quarter over quarter -- the trend line matters more than the level. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- News sentiment is positive (+0.33 across 9 articles, 14d) — News
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
SYRE Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -24.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 81 -- overbought on the larger timeframe too — Technical